Calciphylaxis Risk Factors
The most critical risk factors for calciphylaxis include vitamin K antagonist (warfarin) use (up to 11-fold increased risk), female gender, obesity, diabetes mellitus, chronic kidney disease with dialysis, vitamin K deficiency, inflammation, high-dose active vitamin D derivatives, hyperphosphatemia, elevated alkaline phosphatase, hypoalbuminemia, and hypercoagulable states—particularly lupus anticoagulant and combined thrombophilias. 1
Primary Risk Factors from Guidelines
The 2025 KDIGO guidelines explicitly identify the following as key risk factors 1:
- Vitamin K antagonists (warfarin): Associated with up to 11-fold increased risk in dialysis patients—this is the single most modifiable and dangerous risk factor
- Calcification inducers: High doses of active vitamin D derivatives
- Lack of calcification inhibitors: Vitamin K antagonism or deficiency, inflammation
- Excess calcium and phosphate exposure: While serum levels don't predict outcomes, limiting exposure is considered important
Patient Demographics and Comorbidities
Research consistently demonstrates these demographic patterns 2, 3, 4, 5:
- Female gender: 6-fold higher risk compared to males 4
- Obesity: Strongly associated across multiple studies 2, 5
- Diabetes mellitus: Present in 53% of calciphylaxis patients 2
- Caucasian race: 38% of affected patients 2
- Dialysis status: 79% of calciphylaxis patients are on dialysis 2
Biochemical Risk Factors
Mineral Metabolism Abnormalities
The evidence reveals specific laboratory derangements 3, 4, 5:
- Hyperphosphatemia: Each 1 mg/dL increase in mean serum phosphate increases risk 3.51-fold 4; independent risk factor in Chinese population (OR 4.584) 3
- Elevated alkaline phosphatase: 19% increased risk per 10 IU/L increment 4; independent risk factor (OR 1.179) 3
- Hypoalbuminemia: 21% lower risk for each 0.1 g/dL increase in serum albumin 4; independent risk factor when decreased (OR 1.330) 3
- Calcium-phosphate product >70 mg²/dL²: Significant risk factor 5
- Elevated PTH: Present in 11% at diagnosis, though not consistently an independent predictor 2, 3
Important caveat: The guidelines note that serum calcium and phosphate levels are NOT predictive of outcomes and cannot guide therapy once calciphylaxis develops, but exposure to excess calcium and phosphate before disease onset matters 1.
Hypercoagulable States
A critical and often overlooked category 6:
- Lupus anticoagulant: 48% positive in cases vs 5% in controls (p=0.001); remains significant even in stage 5 CKD (53% vs 0%, p=0.01) 6
- Protein C deficiency: 50% in cases vs 8% in controls (p=0.02) 6
- Combined thrombophilias: 62% in cases vs 31% in controls (p=0.02); highly significant in stage 5 CKD (63% vs 8%, p=0.004) 6
These associations persist even when controlling for warfarin exposure, suggesting an independent pathogenic role.
Medication-Related Risk Factors
Beyond warfarin, other medications implicated 2, 5:
- Vitamin D supplementation: 18% of patients at diagnosis 2
- Calcium phosphate binders: 16% of patients at diagnosis 2
- Systemic corticosteroids: Associated with increased risk 5
Additional Risk Factors
Less commonly emphasized but documented 5:
- Liver disease: Significant association
- Serum aluminum >25 ng/mL: Risk factor in older literature
Clinical Implications for Risk Stratification
High-risk profile requiring vigilance:
- Female dialysis patient
- Obese with diabetes
- On warfarin (consider alternative anticoagulation)
- Hyperphosphatemia with elevated alkaline phosphatase
- Hypoalbuminemia
- Known hypercoagulable state (especially lupus anticoagulant)
- Receiving high-dose active vitamin D
Common pitfall: Assuming normal calcium and phosphate levels at presentation exclude calciphylaxis risk—the damage occurs from chronic exposure, not acute levels 1.
Actionable recommendation: In dialysis patients requiring anticoagulation, strongly consider alternatives to warfarin given the 11-fold increased risk. Screen high-risk patients for hypercoagulable states, particularly lupus anticoagulant and protein C deficiency 6.